- Home
- LVLU vs ATRA Comparison
LVLU vs ATRA Comparison
Compare LVLU & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | ATRA |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 38.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LVLU | ATRA |
|---|---|---|
| Price | $10.10 | $4.89 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 11.9K | ★ 58.9K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | ★ $282,284,000.00 | $120,772,000.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $3.92 |
| 52 Week High | $32.32 | $19.15 |
Technical Indicators
Market Signals| Indicator | LVLU | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 47.50 |
| Support Level | $3.87 | $4.22 |
| Resistance Level | $12.76 | $5.47 |
| Average True Range (ATR) | 1.03 | 0.32 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 33.52 | 34.85 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).